An Open-label, Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder
Latest Information Update: 23 Jun 2020
At a glance
- Drugs Rapastinel (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions; Registrational
- Sponsors Allergan
- 26 Feb 2019 Status changed from active, no longer recruiting to completed.
- 09 Oct 2018 Planned End Date changed from 28 Feb 2020 to 30 Nov 2018.
- 09 Oct 2018 Planned primary completion date changed from 28 Feb 2020 to 30 Nov 2018.